socalTECH

JANUARY 24, 2011

Thousand Oaks-based biotech giant Amgen said Monday afternoon that it is acquiring Biovex , a Woburn, Massachusetts-based developer of treatments for melanoma and head and neck cancer. BioVex develops OncoVEX, a novel oncolytic vaccine in Phase 3 clinical development. READ MORE>>.

Thousand Oaks 167

Thousand Oaks Sales Invest Capital 167

Xconomy

AUGUST 26, 2016

The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. —South San Francisco, CA-based Denali Therapeutics, with ambitions to develop drugs for several neurodegenerative diseases, bagged $130 million in a Series B and unveiled a series of deals.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

AUGUST 5, 2016

Then came the rumor mill: Companies may or may not be approaching Biogen about a sale, and Biogen may or may not be fielding offers. Instead, Holmes promoted a new system, MiniLab , in development. Holmes claimed it would be able to produce multiple test results from a single blood sample without shipping blood to a lab.

News 40

News Thousand Oaks Pricing Report 40